The endorsement means the EMA will offer Carthera support and advice as it moves towards a regulatory filing for its ...

Following positive opinion, Carthera is one of the first companies to benefit from brand-new status – intended to support early access pathways for innovative devices targeting rare diseasesParis, ...

Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for ...

The blood cancer multiple myeloma is deadly. This disease is personal for us because one of our best friends and colleagues ...

As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer ...

Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic ...

‍HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies. In HHT, loss-of-function point mutations in members of the TGF ...

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing ...

Lee Seo-jin has consistently given his viewers numerous works. His intense gaze and commanding presence are ideal for any ...

Amsterdam, The Netherlands Monday, June 23, 2025, 12:00 Hrs [IST] ...